Q2 2018 Newsletter
In this edition please see the updates on pipelines and patent expirations; you will also see some interesting news regarding Novo Nordisk’s oral version of GLP-1 agonist semaglutide (currently in clinical phase 3 clinical trials) reported positive results versus Merck’s DPP-4 Inhibitor Januvia. Making Headlines, President Trump signed the controversial “right-to-try” bill allowing terminally ill patients access to experimental medical treatments not yet approved by the FDA. Also, Takeda announced that it had reached a $62 billion deal to buy Ireland-based Shire in the world’s biggest takeover this year. Takeda’s current top selling drugs include Entyvio, used to treat ulcerative colitis, and cancer drug Leuprorelin. Shire focuses on rare diseases, and it sells Adderall, which is used for ADHD.
Also, we are very excited to announce a few new additions to the Health Delegates team including Anne Nguyen Bradshaw; Director of Clinical Programs, Brian Tackett; Director of Finance and Accounting, and Matthew Kupferberg; General Counsel and Chief Compliance Officer. Please view more about them on the About Us page.
As always, everyone at Health Delegates thanks you for your business and we stand at the ready to assist you and your members in any way possible. Enjoy the Summer Sunshine!
Q1 2018 Newsletter
In this edition please see the updates on pipelines and patent expirations; you will also see some interesting news regarding PCSK9 inhibitors, Sanofi to lower the drug’s net price to within ICER’s range. Making Headlines, Biogen and Abbvie announced that Zinbryta (daclizumab), will be withdrawn from the market worldwide. The decision to discontinue marketing was made following reports of brain inflammation, known as inflammatory encephalitis and meningoencephalitis, in patients taking the drug. Although a removal timeline has not been established, Biogen and AbbVie will work collaboratively with FDA and healthcare providers in the management of Zinbryta patients. We also take a look at Cigna to Buy Express Scripts and CVS Health’s pending $68 billion acquisition of insurer Aetna. As always, everyone at Health Delegates thanks you for your business and we stand at the ready to assist you and your members in any way possible. Happy Spring!